Braun Stacey Associates’s Gilead Sciences GILD Stock Holding History

Braun Stacey Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,055	Closed	-$479K	–	157
2016 Q3	$479K	Sell	6,055 -42,592	-88%	-$3.46M	0.03%	128
2016 Q2	$4.06M	Sell	48,647 -6,680	-12%	-$593K	0.26%	104
2016 Q1	$5.08M	Buy	55,327 +4,170	+8%	+$376K	0.33%	98
2015 Q4	$5.18M	Buy	51,157 +44,380	+655%	+$4.62M	0.33%	96
2015 Q3	$665K	Sell	6,777 -3,893	-36%	-$432K	0.04%	114
2015 Q2	$1.25M	Buy	10,670 +6,805	+176%	+$744K	0.05%	183
2015 Q1	$379K	Sell	3,865 -8,170	-68%	-$830K	0.02%	129
2014 Q4	$1.13M	Buy	12,035 +6,110	+103%	+$632K	0.07%	111
2014 Q3	$631K	Buy	5,925 +3,075	+108%	+$301K	0.04%	117
2014 Q2	$236K	Buy	+2,850	New	+$222K	0.01%	151

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Braun Stacey Associates's GILD Position: Q4 2016 in Review

Braun Stacey Associates sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 6,055 shares — an estimated $479K sold.

Braun Stacey Associates first reported a position in GILD in Q2 2014 and held it in 10 quarters. The position peaked at $5.18M in Q4 2015. 1,572 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

Braun Stacey Associates reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
Braun Stacey Associates sold 6,055 Gilead Sciences shares in Q4 2016, an estimated $479K.
Braun Stacey Associates first reported a position in Gilead Sciences in Q2 2014 and held it in 10 quarters.
Braun Stacey Associates's Gilead Sciences position peaked at $5.18M in Q4 2015.
1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Braun Stacey Associates's 13F filing for Q4 2016, filed 26 Jan 2017.